Anrukinzumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL13 |
| Identifiers | |
| CAS Number | 910649-32-0  |
| ATC code | none |
| UNII | OU46IGC49F  |
| Chemical data | |
| Formula | C6452H9954N1714O2024S46 |
| Molecular mass | 145.4 kg/mol |
| (what is this?) (verify) |
|
Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]
Anrukinzumab was developed by Wyeth.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibody stubs
- Wyeth
